Provider Networks & CINs
Expert articles and analysis related to provider networks & cins.
AI Summary â Last 30 Days
CMS is continuing to widen mandatory and semi-mandatory value-based payment infrastructure under the Trump administration, with expanded joint replacement model participation expected by 2028 and ongoing operational follow-through on APM incentive paymentsâsignals that specialty networks, post-acute partners, and CIN-aligned referral pathways will face more direct accountability for episode cost and outcomes. Independent primary care is also being courted through lower-risk ACO vehicles, including First Point ACOâs 70/30 shared-savings model with no downside risk, while private capital-backed enablement platforms such as Aligned Marketplace target the persistent gap between fragmented primary care capacity and payer demand for scalable risk-bearing networks. For provider networks and CINs, the strategic tension is sharpening: build enough actuarial, referral-management, and care-management capability to participate in models like expanded joint replacement and ACO arrangements, while protecting independent physicians from premature downside exposure and margin pressure from Medicare payment updates such as the proposed 2027 outpatient/ASC rule. CMS joint replacement expansion First Point ACO shared-savings model
Related Articles
What appeals court 340B rebate decision means for federal rebates
An appeals court barred 340B rebate programs by drug manufacturers, among recent legal developments. The case could have ramifications for federal 340B rebates. On July 21, the U.S. Court of Appeals f...
Drug pricing and the IRA: Tracking the government's negotiation power
Drug pricing and the IRA: Tracking the government's negotiation power  Endpoints News
The Drug Changing Medicine
By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor agonists, the drug cla...
Medicaid MFN Pricing Could Save $8.6 Billion
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility  MedCity News
Brand Drugmakersâ Patent Abuse Is Raising Americansâ Healthcare Costs by Billions Each Year
Brand Drugmakersâ Patent Abuse Is Raising Americansâ Healthcare Costs by Billions Each Year  AHIP
Whatâs Next For Prescription Drug Affordability Boards After Amgen v. Mizner?
Whatâs Next For Prescription Drug Affordability Boards After Amgen v. Mizner?  Health Affairs
New Analysis Highlights Opportunities to Improve MPPP Uptake
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight  HCI Innovation Group
Court rules that companies may not impose 340B rebate model without HHS approval
Court rules that companies may not impose 340B rebate model without HHS approval  American Hospital Association